Valneva's Stock Outlook Amid Regulatory Challenges

First Berlin Equity Research has released a research update on Valneva SE, maintaining a "Buy" recommendation but lowering the target price from €8.10 to €6.30. This adjustment follows the FDA's suspension of the chikungunya vaccine, IXCHIQ, due to four serious adverse events. The suspension may impact vaccine orders outside the U.S., potentially benefiting Bavarian Nordic's competing vaccine, VIMKUNYA. Despite this setback, Valneva's Lyme disease vaccine candidate, VLA15, holds promise. The phase 3 trial results are expected soon, with a market launch planned by Pfizer in autumn 2027. Valneva anticipates significant milestone payments and royalties from this endeavor.